Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial)
Identifieur interne : 002F46 ( PascalFrancis/Curation ); précédent : 002F45; suivant : 002F47Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial)
Auteurs : Herbert D. Aronow [États-Unis] ; Robert M. Califf [États-Unis] ; Robert A. Harrington [États-Unis] ; Marc Vallee [États-Unis] ; Carmelo Graffagnino [États-Unis] ; Ashfaq Shuaib [Canada] ; Desmond J. Fitzgerald [Irlande (pays)] ; J. Donald Easton [États-Unis] ; Frans Van De Werf [Belgique] ; Hans-Christoph Diener [Allemagne] ; James Ferguson [États-Unis] ; Peter J. Koudstaal [Pays-Bas] ; Pierre Amarenco [France] ; Pierre Theroux [Canada] ; Stephen Davis [Australie] ; Eric J. Topol [États-Unis]Source :
- The American journal of cardiology [ 0002-9149 ] ; 2008.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
Despite aspirin's established role in the treatment of atherosclerotic vascular disease, considerable controversy exists regarding its most effective dosing strategy. In a retrospective observational study, we examined the relation between prescribed aspirin dose (<162 mg vs ≥162 mg/day aspirin) and clinical outcome in 4,589 placebo-treated patients enrolled in the Blockage of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial over a median follow-up of 366 days. Standard Cox regression analysis was employed because propensity analysis was not feasible. Compared with lower aspirin doses, higher doses were associated with lower unadjusted all-cause mortality (2.9 vs 1.6%, respectively; log rank chi-square 8.6, p = 0.0034). Higher aspirin dose remained independently predictive of lower all-cause mortality in a multivariable Cox proportional hazards model (hazard ratio 0.64, 95% confidence interval 0.42 to 0.97, p = 0.037). However, there was no significant difference in the incidence of the composite endpoint death, nonfatal myocardial infarction, or nonfatal stroke (6.1% vs 6.2%, p = 0.74). Higher aspirin dose was a significant independent predictor of any (hazard ratio 1.32, 95% confidence interval 1.12 to 1.55, p = 0.001) but not serious bleeding. In conclusion, our findings suggest that aspirin doses of ≥ 162 mg/day may be more beneficial than those <162 mg/day at preventing death.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003071
Links to Exploration step
Pascal:09-0037296Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial)</title><author><name sortKey="Aronow, Herbert D" sort="Aronow, Herbert D" uniqKey="Aronow H" first="Herbert D." last="Aronow">Herbert D. Aronow</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Scholars Program, Michigan Heart and Vascular Institute at St. Joseph Mercy Hospital</s1><s2>Ann Arbor, Michigan</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Califf, Robert M" sort="Califf, Robert M" uniqKey="Califf R" first="Robert M." last="Califf">Robert M. Califf</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke Clinical Research Institute, Duke University</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Harrington, Robert A" sort="Harrington, Robert A" uniqKey="Harrington R" first="Robert A." last="Harrington">Robert A. Harrington</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke Clinical Research Institute, Duke University</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Vallee, Marc" sort="Vallee, Marc" uniqKey="Vallee M" first="Marc" last="Vallee">Marc Vallee</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke Clinical Research Institute, Duke University</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Graffagnino, Carmelo" sort="Graffagnino, Carmelo" uniqKey="Graffagnino C" first="Carmelo" last="Graffagnino">Carmelo Graffagnino</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, Duke University</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Shuaib, Ashfaq" sort="Shuaib, Ashfaq" uniqKey="Shuaib A" first="Ashfaq" last="Shuaib">Ashfaq Shuaib</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Neurology, University of Alberta</s1><s2>Edmonton</s2><s3>CAN</s3><sZ>6 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Fitzgerald, Desmond J" sort="Fitzgerald, Desmond J" uniqKey="Fitzgerald D" first="Desmond J." last="Fitzgerald">Desmond J. Fitzgerald</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Clinical Pharmacology, Royal College of Surgeons in Ireland</s1><s2>Dublin</s2><s3>IRL</s3><sZ>7 aut.</sZ></inist:fA14><country>Irlande (pays)</country></affiliation></author><author><name sortKey="Easton, J Donald" sort="Easton, J Donald" uniqKey="Easton J" first="J. Donald" last="Easton">J. Donald Easton</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Rhode Island Hospital and Brown University</s1><s2>Providence, Rhode Island</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Van De Werf, Frans" sort="Van De Werf, Frans" uniqKey="Van De Werf F" first="Frans" last="Van De Werf">Frans Van De Werf</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Cardiology, University Hospital Gasthuisberg</s1><s2>Leuven</s2><s3>BEL</s3><sZ>9 aut.</sZ></inist:fA14><country>Belgique</country></affiliation></author><author><name sortKey="Diener, Hans Christoph" sort="Diener, Hans Christoph" uniqKey="Diener H" first="Hans-Christoph" last="Diener">Hans-Christoph Diener</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Neurology University Duisburg-Essen</s1><s2>Essen</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country></affiliation></author><author><name sortKey="Ferguson, James" sort="Ferguson, James" uniqKey="Ferguson J" first="James" last="Ferguson">James Ferguson</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Texas Heart Institute at St Luke's Episcopal Hospital</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Koudstaal, Peter J" sort="Koudstaal, Peter J" uniqKey="Koudstaal P" first="Peter J." last="Koudstaal">Peter J. Koudstaal</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Neurology, Erasmus Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>12 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Amarenco, Pierre" sort="Amarenco, Pierre" uniqKey="Amarenco P" first="Pierre" last="Amarenco">Pierre Amarenco</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurology and Stroke Center, Bichat University Hospital, Denis Diderot University and Medical School</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Theroux, Pierre" sort="Theroux, Pierre" uniqKey="Theroux P" first="Pierre" last="Theroux">Pierre Theroux</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Montreal Heart Institute and University of Montreal</s1><s2>Montreal</s2><s3>CAN</s3><sZ>14 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Davis, Stephen" sort="Davis, Stephen" uniqKey="Davis S" first="Stephen" last="Davis">Stephen Davis</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Division of Neurology, Royal Melbourne Hospital, University of Melbourne</s1><s3>AUS</s3><sZ>15 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Topol, Eric J" sort="Topol, Eric J" uniqKey="Topol E" first="Eric J." last="Topol">Eric J. Topol</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Division of Cardiovascular Diseases, Scripps Clinic</s1><s2>La Jolla, California</s2><s3>USA</s3><sZ>16 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0037296</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 09-0037296 INIST</idno><idno type="RBID">Pascal:09-0037296</idno><idno type="wicri:Area/PascalFrancis/Corpus">003071</idno><idno type="wicri:Area/PascalFrancis/Curation">002F46</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial)</title><author><name sortKey="Aronow, Herbert D" sort="Aronow, Herbert D" uniqKey="Aronow H" first="Herbert D." last="Aronow">Herbert D. Aronow</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Scholars Program, Michigan Heart and Vascular Institute at St. Joseph Mercy Hospital</s1><s2>Ann Arbor, Michigan</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Califf, Robert M" sort="Califf, Robert M" uniqKey="Califf R" first="Robert M." last="Califf">Robert M. Califf</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke Clinical Research Institute, Duke University</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Harrington, Robert A" sort="Harrington, Robert A" uniqKey="Harrington R" first="Robert A." last="Harrington">Robert A. Harrington</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke Clinical Research Institute, Duke University</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Vallee, Marc" sort="Vallee, Marc" uniqKey="Vallee M" first="Marc" last="Vallee">Marc Vallee</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke Clinical Research Institute, Duke University</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Graffagnino, Carmelo" sort="Graffagnino, Carmelo" uniqKey="Graffagnino C" first="Carmelo" last="Graffagnino">Carmelo Graffagnino</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, Duke University</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Shuaib, Ashfaq" sort="Shuaib, Ashfaq" uniqKey="Shuaib A" first="Ashfaq" last="Shuaib">Ashfaq Shuaib</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Neurology, University of Alberta</s1><s2>Edmonton</s2><s3>CAN</s3><sZ>6 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Fitzgerald, Desmond J" sort="Fitzgerald, Desmond J" uniqKey="Fitzgerald D" first="Desmond J." last="Fitzgerald">Desmond J. Fitzgerald</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Clinical Pharmacology, Royal College of Surgeons in Ireland</s1><s2>Dublin</s2><s3>IRL</s3><sZ>7 aut.</sZ></inist:fA14><country>Irlande (pays)</country></affiliation></author><author><name sortKey="Easton, J Donald" sort="Easton, J Donald" uniqKey="Easton J" first="J. Donald" last="Easton">J. Donald Easton</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Rhode Island Hospital and Brown University</s1><s2>Providence, Rhode Island</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Van De Werf, Frans" sort="Van De Werf, Frans" uniqKey="Van De Werf F" first="Frans" last="Van De Werf">Frans Van De Werf</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Cardiology, University Hospital Gasthuisberg</s1><s2>Leuven</s2><s3>BEL</s3><sZ>9 aut.</sZ></inist:fA14><country>Belgique</country></affiliation></author><author><name sortKey="Diener, Hans Christoph" sort="Diener, Hans Christoph" uniqKey="Diener H" first="Hans-Christoph" last="Diener">Hans-Christoph Diener</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Neurology University Duisburg-Essen</s1><s2>Essen</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country></affiliation></author><author><name sortKey="Ferguson, James" sort="Ferguson, James" uniqKey="Ferguson J" first="James" last="Ferguson">James Ferguson</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Texas Heart Institute at St Luke's Episcopal Hospital</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Koudstaal, Peter J" sort="Koudstaal, Peter J" uniqKey="Koudstaal P" first="Peter J." last="Koudstaal">Peter J. Koudstaal</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Neurology, Erasmus Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>12 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Amarenco, Pierre" sort="Amarenco, Pierre" uniqKey="Amarenco P" first="Pierre" last="Amarenco">Pierre Amarenco</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurology and Stroke Center, Bichat University Hospital, Denis Diderot University and Medical School</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Theroux, Pierre" sort="Theroux, Pierre" uniqKey="Theroux P" first="Pierre" last="Theroux">Pierre Theroux</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Montreal Heart Institute and University of Montreal</s1><s2>Montreal</s2><s3>CAN</s3><sZ>14 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Davis, Stephen" sort="Davis, Stephen" uniqKey="Davis S" first="Stephen" last="Davis">Stephen Davis</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Division of Neurology, Royal Melbourne Hospital, University of Melbourne</s1><s3>AUS</s3><sZ>15 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Topol, Eric J" sort="Topol, Eric J" uniqKey="Topol E" first="Eric J." last="Topol">Eric J. Topol</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Division of Cardiovascular Diseases, Scripps Clinic</s1><s2>La Jolla, California</s2><s3>USA</s3><sZ>16 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></analytic><series><title level="j" type="main">The American journal of cardiology</title><title level="j" type="abbreviated">Am. j. cardiol.</title><idno type="ISSN">0002-9149</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The American journal of cardiology</title><title level="j" type="abbreviated">Am. j. cardiol.</title><idno type="ISSN">0002-9149</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetylsalicylic acid</term><term>Cardiology</term><term>Cause</term><term>Circulatory system</term><term>Coronary artery</term><term>Coronary heart disease</term><term>Dose</term><term>Epidemiology</term><term>Hemorrhage</term><term>Human</term><term>Ischemia</term><term>Mortality</term><term>Posology</term><term>Prognosis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Hémorragie</term><term>Cardiopathie coronaire</term><term>Ischémie</term><term>Acide acétylsalicylique</term><term>Dose</term><term>Posologie</term><term>Cause</term><term>Mortalité</term><term>Pronostic</term><term>Epidémiologie</term><term>Homme</term><term>Artère coronaire</term><term>Appareil circulatoire</term><term>Cardiologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Mortalité</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Despite aspirin's established role in the treatment of atherosclerotic vascular disease, considerable controversy exists regarding its most effective dosing strategy. In a retrospective observational study, we examined the relation between prescribed aspirin dose (<162 mg vs ≥162 mg/day aspirin) and clinical outcome in 4,589 placebo-treated patients enrolled in the Blockage of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial over a median follow-up of 366 days. Standard Cox regression analysis was employed because propensity analysis was not feasible. Compared with lower aspirin doses, higher doses were associated with lower unadjusted all-cause mortality (2.9 vs 1.6%, respectively; log rank chi-square 8.6, p = 0.0034). Higher aspirin dose remained independently predictive of lower all-cause mortality in a multivariable Cox proportional hazards model (hazard ratio 0.64, 95% confidence interval 0.42 to 0.97, p = 0.037). However, there was no significant difference in the incidence of the composite endpoint death, nonfatal myocardial infarction, or nonfatal stroke (6.1% vs 6.2%, p = 0.74). Higher aspirin dose was a significant independent predictor of any (hazard ratio 1.32, 95% confidence interval 1.12 to 1.55, p = 0.001) but not serious bleeding. In conclusion, our findings suggest that aspirin doses of ≥ 162 mg/day may be more beneficial than those <162 mg/day at preventing death.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0002-9149</s0></fA01><fA02 i1="01"><s0>AJCDAG</s0></fA02><fA03 i2="1"><s0>Am. j. cardiol.</s0></fA03><fA05><s2>102</s2></fA05><fA06><s2>10</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial)</s1></fA08><fA11 i1="01" i2="1"><s1>ARONOW (Herbert D.)</s1></fA11><fA11 i1="02" i2="1"><s1>CALIFF (Robert M.)</s1></fA11><fA11 i1="03" i2="1"><s1>HARRINGTON (Robert A.)</s1></fA11><fA11 i1="04" i2="1"><s1>VALLEE (Marc)</s1></fA11><fA11 i1="05" i2="1"><s1>GRAFFAGNINO (Carmelo)</s1></fA11><fA11 i1="06" i2="1"><s1>SHUAIB (Ashfaq)</s1></fA11><fA11 i1="07" i2="1"><s1>FITZGERALD (Desmond J.)</s1></fA11><fA11 i1="08" i2="1"><s1>EASTON (J. Donald)</s1></fA11><fA11 i1="09" i2="1"><s1>VAN DE WERF (Frans)</s1></fA11><fA11 i1="10" i2="1"><s1>DIENER (Hans-Christoph)</s1></fA11><fA11 i1="11" i2="1"><s1>FERGUSON (James)</s1></fA11><fA11 i1="12" i2="1"><s1>KOUDSTAAL (Peter J.)</s1></fA11><fA11 i1="13" i2="1"><s1>AMARENCO (Pierre)</s1></fA11><fA11 i1="14" i2="1"><s1>THEROUX (Pierre)</s1></fA11><fA11 i1="15" i2="1"><s1>DAVIS (Stephen)</s1></fA11><fA11 i1="16" i2="1"><s1>TOPOL (Eric J.)</s1></fA11><fA14 i1="01"><s1>Clinical Scholars Program, Michigan Heart and Vascular Institute at St. Joseph Mercy Hospital</s1><s2>Ann Arbor, Michigan</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Duke Clinical Research Institute, Duke University</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="03"><s1>Division of Neurology, Duke University</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="04"><s1>Division of Neurology, University of Alberta</s1><s2>Edmonton</s2><s3>CAN</s3><sZ>6 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Clinical Pharmacology, Royal College of Surgeons in Ireland</s1><s2>Dublin</s2><s3>IRL</s3><sZ>7 aut.</sZ></fA14><fA14 i1="06"><s1>Rhode Island Hospital and Brown University</s1><s2>Providence, Rhode Island</s2><s3>USA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Cardiology, University Hospital Gasthuisberg</s1><s2>Leuven</s2><s3>BEL</s3><sZ>9 aut.</sZ></fA14><fA14 i1="08"><s1>Department of Neurology University Duisburg-Essen</s1><s2>Essen</s2><s3>DEU</s3><sZ>10 aut.</sZ></fA14><fA14 i1="09"><s1>Texas Heart Institute at St Luke's Episcopal Hospital</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>11 aut.</sZ></fA14><fA14 i1="10"><s1>Department of Neurology, Erasmus Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>12 aut.</sZ></fA14><fA14 i1="11"><s1>Department of Neurology and Stroke Center, Bichat University Hospital, Denis Diderot University and Medical School</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ></fA14><fA14 i1="12"><s1>Montreal Heart Institute and University of Montreal</s1><s2>Montreal</s2><s3>CAN</s3><sZ>14 aut.</sZ></fA14><fA14 i1="13"><s1>Division of Neurology, Royal Melbourne Hospital, University of Melbourne</s1><s3>AUS</s3><sZ>15 aut.</sZ></fA14><fA14 i1="14"><s1>Division of Cardiovascular Diseases, Scripps Clinic</s1><s2>La Jolla, California</s2><s3>USA</s3><sZ>16 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>BRAVO Trial Investigators</s1><s3>INC</s3></fA17><fA20><s1>1285-1290</s1></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>8674</s2><s5>354000184553870010</s5></fA43><fA44><s0>0000</s0><s1>© 2009 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>18 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>09-0037296</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>The American journal of cardiology</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Despite aspirin's established role in the treatment of atherosclerotic vascular disease, considerable controversy exists regarding its most effective dosing strategy. In a retrospective observational study, we examined the relation between prescribed aspirin dose (<162 mg vs ≥162 mg/day aspirin) and clinical outcome in 4,589 placebo-treated patients enrolled in the Blockage of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial over a median follow-up of 366 days. Standard Cox regression analysis was employed because propensity analysis was not feasible. Compared with lower aspirin doses, higher doses were associated with lower unadjusted all-cause mortality (2.9 vs 1.6%, respectively; log rank chi-square 8.6, p = 0.0034). Higher aspirin dose remained independently predictive of lower all-cause mortality in a multivariable Cox proportional hazards model (hazard ratio 0.64, 95% confidence interval 0.42 to 0.97, p = 0.037). However, there was no significant difference in the incidence of the composite endpoint death, nonfatal myocardial infarction, or nonfatal stroke (6.1% vs 6.2%, p = 0.74). Higher aspirin dose was a significant independent predictor of any (hazard ratio 1.32, 95% confidence interval 1.12 to 1.55, p = 0.001) but not serious bleeding. In conclusion, our findings suggest that aspirin doses of ≥ 162 mg/day may be more beneficial than those <162 mg/day at preventing death.</s0></fC01><fC02 i1="01" i2="X"><s0>002B12A03</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Hémorragie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Hemorrhage</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Hemorragia</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Cardiopathie coronaire</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Coronary heart disease</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Cardiopatía coronaria</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Ischémie</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Ischemia</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Isquemia</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Acide acétylsalicylique</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Acetylsalicylic acid</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Acetilsalicilico ácido</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Dose</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Dose</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Dosis</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Posologie</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Posology</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Posología</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Cause</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Cause</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Causa</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Mortalité</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Mortality</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Mortalidad</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Pronostic</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Prognosis</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Pronóstico</s0><s5>14</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Epidémiologie</s0><s5>15</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Epidemiology</s0><s5>15</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Epidemiología</s0><s5>15</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Homme</s0><s5>16</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Human</s0><s5>16</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Hombre</s0><s5>16</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Artère coronaire</s0><s5>17</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Coronary artery</s0><s5>17</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Arteria coronaria</s0><s5>17</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Appareil circulatoire</s0><s5>18</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Circulatory system</s0><s5>18</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Aparato circulatorio</s0><s5>18</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Cardiologie</s0><s5>19</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Cardiology</s0><s5>19</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Cardiología</s0><s5>19</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0><s5>37</s5></fC07><fN21><s1>026</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F46 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002F46 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:09-0037296
|texte= Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial)
}}
| This area was generated with Dilib version V0.6.33. |  |